Trust Signals
Sources: PubMed, PMC, published clinical trial registries, regulatory agency databases.
Conflict of interest: FormBlends sells research-grade peptides. This page grades evidence honestly, including evidence against efficacy.
Standard: Claims are graded by evidence type. Speculative claims are labeled speculative. No fabricated statistics.
Key Takeaways
- Cerebrolysin is the only peptide-based option on this list with multiple completed human RCTs showing cognitive benefit, specifically in stroke rehabilitation and Alzheimer's disease patients.
- Semax elevates BDNF in human subjects at intranasal doses studied in Russian clinical literature, but Western replication trials are absent and sample sizes are small.
- Dihexa activates the HGF/Met pathway and outperforms BDNF in rodent dendritic spine assays by several orders of magnitude in potency, yet zero human data exists.
- Most orally dosed peptides marketed for brain function face near-complete proteolytic destruction before reaching systemic circulation, making route of administration a non-negotiable variable.
- A credible certificate of analysis for any research peptide must show HPLC purity above 98% and mass spectrometry sequence confirmation; absence of either is a disqualifying sourcing red flag.
What Are the Best Peptides for Brain Function?
The best peptides for brain function, ranked by quality of human evidence, are Cerebrolysin, Semax, Selank, BPC-157, and Dihexa. Cerebrolysin leads on clinical trial depth. Semax and Selank have documented human signals. BPC-157 and Dihexa have compelling animal data but no human neurological trials. None are FDA-approved cognitive enhancers.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Every Major Claim Graded
- How Do These Peptides Actually Affect the Brain?
- The Five Best Peptides for Brain Function, Ranked
- What Most Peptide Listicles Get Wrong
- Do Peptides Cross the Blood-Brain Barrier?
- Honest Head-to-Head: Peptides vs Proven Alternatives
- How to Read a COA and Judge a Product
- Stability and Formulation: The Gotcha Nobody Covers
- FAQ
- Sources
Evidence Ledger: Every Major Claim Graded
| Peptide / Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Cerebrolysin improves cognitive scales in Alzheimer's | Multiple human RCTs (e.g., Alvarez et al., 2006; Muresanu et al., 2008) | Modest positive | Moderate |
| Cerebrolysin aids stroke rehabilitation | Human RCTs including CASTA trial (Muresanu et al., 2016) | Positive for functional recovery | Moderate |
| Semax elevates BDNF in human subjects | Small human trials (Russian literature; Dolotov et al. 2006 animal mechanistic) | Positive, BDNF increase | Low |
| Semax improves attention/processing in humans | Small human trials, not replicated in Western RCTs | Tentatively positive | Low |
| Selank reduces anxiety with mild nootropic effect | Small Russian human trials; GABAergic mechanism in rodents | Positive for anxiety, unclear for cognition | Low |
| Dihexa promotes dendritic spine growth | Rodent studies (McCoy et al., Washington State University) | Strongly positive in animals | Very Low (no human data) |
| BPC-157 reverses dopaminergic deficits | Rodent models | Positive in animals | Very Low (no human neurological trials) |
| Epithalon extends lifespan / slows brain aging | Animal studies, one small human oncology series | Unclear direction in healthy humans | Very Low |
How Do These Peptides Actually Affect the Brain?
Semax (ACTH 4-10 analog, 7 amino acids). Semax is a synthetic analog of a fragment of adrenocorticotropic hormone. Its primary documented mechanism is upregulation of BDNF (brain-derived neurotrophic factor) mRNA expression and promotion of NGF (nerve growth factor) in cortical and hippocampal tissue, demonstrated in rodent models by Dolotov et al. (2006). BDNF is the primary driver of hippocampal neuroplasticity and long-term potentiation. Semax also modulates serotonin and dopamine turnover in prefrontal regions in animal studies. The honest caveat: BDNF upregulation in a rodent cortex does not prove that intranasal Semax in humans produces the same magnitude of BDNF increase, or that the increase translates to measurable memory gains.
Dihexa (PNB-0408, hepatocyte growth factor fragment). Dihexa is a heptapeptide derived from angiotensin IV. Research from Washington State University (McCoy et al.) demonstrated that Dihexa activates the HGF/Met receptor tyrosine kinase system, which drives synaptogenesis and dendritic spine density. The rodent potency data showed activity at concentrations roughly a million-fold lower than BDNF for certain synaptic endpoints, which generated significant scientific interest. The honest caveat: receptor potency in vitro and in rodent hippocampal slices does not equal efficacy or safety in humans. No human pharmacokinetic or efficacy data has been published.
Cerebrolysin (mixture of low-molecular-weight peptides under 10 kDa). Derived from porcine brain protein, Cerebrolysin contains multiple peptide fragments that collectively mimic neurotrophic factor activity, including BDNF-like and NGF-like actions. Its heterogeneous composition means it is difficult to attribute effect to a single peptide. Proposed mechanisms include reduction of amyloid precursor protein processing, attenuation of tau hyperphosphorylation, and direct anti-apoptotic signaling in neurons. These mechanisms are supported by in vitro and animal data; the clinical RCT data shows modest benefit on Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scores and functional outcomes in stroke patients.
BPC-157 (Body Protection Compound, 15 amino acids). BPC-157 was originally isolated from human gastric juice. Its CNS-relevant mechanisms in rodent studies include upregulation of dopamine D1 and D2 receptor expression in the striatum, and modulation of nitric oxide pathways. Studies in rats with induced dopaminergic lesions (modeling Parkinson-like states) showed partial behavioral and neurochemical restoration. There is also evidence of interaction with the serotonergic system. The honest caveat: all neurological evidence in BPC-157 is from rodent models. Its well-known tendon and gut data in animals does not transfer automatically to a brain benefit claim.
The Five Best Peptides for Brain Function, Ranked
1. Cerebrolysin. Highest human evidence quality. Administered IV or IM; not practical for self-experimentation. The only option here with replication across multiple independent research groups. Best suited for clinical neurological contexts (post-stroke, mild-to-moderate Alzheimer's). Limitations include porcine sourcing, batch-to-batch compositional variability, and parenteral-only delivery.
2. Semax. The most documented intranasal research peptide for cognition. Russian regulatory approval for ischemic stroke and cognitive impairment exists, though this does not constitute FDA validation. Studied doses in human clinical literature range from roughly 600 mcg to 3,000 mcg intranasally per day. Key signal is BDNF pathway engagement; key gap is absence of independent Western RCTs.
3. Selank. A heptapeptide tuftsin analog with a documented anxiolytic profile and mild cognitive effects, particularly in anxiety-impaired cognition. Acts partly through increasing enkephalin stability and modulating the GABAergic system. A good evidence base for anxiety reduction from Russian human trials; weaker evidence for pure cognitive enhancement in non-anxious individuals. Less stimulating than Semax.
4. BPC-157. Strong rodent data for dopaminergic neuroprotection and gut-brain axis effects. Relevance to brain function in healthy humans is extrapolated, not demonstrated. Included because its mechanistic profile is credible and it is one of the most widely studied research peptides overall, but users should understand they are operating entirely on animal-to-human extrapolation for neurological endpoints.
5. Dihexa. Placed fifth not because its mechanism is weak (it is compelling) but because the human evidence gap is total. The potency of HGF/Met activation in rodent hippocampal assays is remarkable, but without pharmacokinetic data in humans, dose selection is genuinely unknown. Dihexa is the highest-risk, highest-speculation entry on this list.
What Most Peptide Listicles Get Wrong
Most competitor pages omit three critical facts.
First, they treat Russian regulatory approval as equivalent to FDA approval. Semax and Selank are approved medications in Russia. This means they passed Russian regulatory standards, which differ from FDA standards in trial design requirements and sample size thresholds. Russian regulatory approval is meaningful as a signal that some safety and efficacy evidence exists, but it is not interchangeable with an FDA-approved drug designation.
Second, they ignore compositional instability in Cerebrolysin. Because Cerebrolysin is a hydrolysate from porcine brain, batch-to-batch peptide composition is not precisely fixed. Clinical trials use standardized commercial preparations (Schwabe Pharma). A compounded or gray-market version cannot be assumed to contain the same peptide profile as the clinical trial product. This matters enormously when evaluating whether a purchased product will replicate trial results.
Third, they list oral versions of peptides without acknowledging proteolytic destruction. Semax taken orally, for example, would be digested in the stomach and small intestine before reaching systemic circulation. The relevant clinical data for Semax is intranasal. Listing an oral Semax product with the same implied efficacy as intranasal Semax is either ignorance or misleading marketing.
Do Peptides Cross the Blood-Brain Barrier?
This is the single most important pharmacological question for brain-targeted peptides and most pages skip it entirely.
The blood-brain barrier (BBB) is a system of tight junctions between cerebral capillary endothelial cells, supported by astrocytic end-feet, that restricts passage of most molecules based on size, charge, and lipophilicity. The general rule is that molecules above roughly 400 to 600 Daltons and with high polarity cross the BBB poorly via passive diffusion. Most research peptides exceed this threshold.
The intranasal route bypasses the BBB via the olfactory and trigeminal nerve pathways, allowing transport directly into the olfactory bulb and then to deeper brain structures along axonal and perivascular routes. This is why intranasal administration is specifically used for Semax and Selank rather than injection. Even so, CNS delivery by this route is partial, not complete, and varies with nasal mucosa health, formulation pH, and particle size.
Cerebrolysin requires IV or IM administration; its peptide fragments are small enough (under 10 kDa) that some cross the BBB via active transport mechanisms, but the BBB crossing efficiency is still not 100% and depends on preparation.
Dihexa is notably lipophilic relative to most peptides, which may account for some of its CNS penetration in rodent studies, but human BBB pharmacokinetics remain unpublished.
Honest Head-to-Head: Peptides vs Proven Alternatives
| Option | Best Evidence Type | Approved Use | Effect Size (cognition) | Peptide Wins? |
|---|---|---|---|---|
| Cerebrolysin | Multiple human RCTs | Yes (Europe, Asia; not FDA) | Modest (ADAS-cog improvement) | Comparable to approved agents in some trials |
| Modafinil | Multiple large RCTs | FDA approved (narcolepsy, shift work) | Strong for attention in sleep-deprived | No. Modafinil wins for wakefulness and attention with much stronger evidence. |
| Donepezil (acetylcholinesterase inhibitor) | Multiple large RCTs | FDA approved (Alzheimer's) | Moderate for Alzheimer's population | No. Donepezil wins in the Alzheimer's indication. |
| Semax | Small human trials (Russian) | Russia only | Unclear magnitude | Plausible in mechanisms; cannot beat approved drugs on evidence volume. |
| Piracetam (racetam) | Mixed RCT data | Not FDA approved | Small to moderate, inconsistent | Draw. Similar evidence quality to Semax/Selank; more Western trial data available. |
| Dihexa / BPC-157 | Rodent only (CNS) | None | Unknown in humans | No. Every proven option wins on evidence. These are speculative. |
How to Read a COA and Judge a Product
A certificate of analysis (COA) from a research peptide supplier should contain the following and you should be able to verify each line.
HPLC purity. High-performance liquid chromatography separates the peptide from impurities by retention time. A purity figure of 98% or above by area-under-curve is the standard for research-grade peptides. Products showing 95% purity contain roughly 5% unknown material, which may include deletion sequences (peptides missing one or more amino acids) or oxidized variants. For brain-targeted compounds, you want the highest purity available.
Mass spectrometry (MS) confirmation. The COA should show a measured molecular weight matching the theoretical molecular weight of the peptide. For Semax (MEHFPGP, 7 amino acids), the molecular weight is approximately 887 Daltons. For BPC-157 (15 amino acids), it is approximately 1,419 Daltons. If the measured mass deviates by more than a fraction of a Dalton from theoretical, sequence integrity is in question.
Endotoxin testing. Bacterial lipopolysaccharide contamination (endotoxins) causes inflammatory responses and is dangerous at low levels when injected or intranasally administered. The LAL (Limulus amebocyte lysate) assay or a recombinant equivalent should show endotoxin levels below relevant thresholds (commonly less than 1 EU/mg for research compounds).
Moisture content. Lyophilized peptides absorb water from the air, which reduces actual peptide content per vial. Karl Fischer titration for moisture content above roughly 6 to 8% should prompt caution about actual dose delivered per stated weight.
What a degraded product looks like. Lyophilized peptide should appear as a white to off-white powder or a cohesive cake. Yellow or brown discoloration suggests oxidation. A reconstituted solution that is cloudy, shows particulates, or has an unexpected color should not be used. Semax in particular contains a methionine residue that is susceptible to oxidation; oxidized methionine-containing peptides lose biological activity.
Stability and Formulation: The Gotcha Nobody Covers
This is the highest-value section for anyone who has ever purchased a peptide and wondered whether it was still good.
Why peptides degrade in solution. In aqueous solution, peptide bonds are susceptible to hydrolysis, and individual amino acid side chains undergo specific reactions. Methionine (present in Semax as the N-terminal residue) oxidizes to methionine sulfoxide in the presence of dissolved oxygen or light-generated reactive oxygen species. This is a chemical change to the residue itself, not just a loss of the molecule. Oxidized Semax has reduced BDNF-stimulating activity in cell assays. The fix is to minimize reconstituted volume (reduce exposure to oxygen), store in amber vials, and use bacteriostatic water (benzyl alcohol inhibits microbial growth but does not prevent chemical oxidation).
Freeze-thaw cycles. Each cycle of freezing and thawing promotes aggregation of peptide molecules into non-bioavailable clumps. Best practice is to aliquot a reconstituted peptide into single-use volumes before freezing so the main stock is never repeatedly thawed. Most peptide sources recommend using reconstituted solution within 4 to 6 weeks under refrigeration (2 to 8 degrees Celsius), though specific degradation kinetics vary by peptide and are not always published for research compounds.
Lyophilized powder storage. Unreconstituted powder is far more stable. Storage at minus 20 degrees Celsius in a sealed, desiccated container with minimal light exposure preserves potency for months to years in most published stability data on peptide drugs. Domestic freezer fluctuations (from door opening) matter; a dedicated laboratory freezer at stable minus 20 is meaningfully better than a typical household freezer.
Intranasal formulation pH. The nasal mucosa tolerates a pH range of roughly 4.5 to 6.5. Reconstituting in plain sterile water (pH roughly 7) is outside this range and may cause mucosal irritation with repeated use. Properly formulated intranasal peptides use phosphate buffered saline or citrate buffer to achieve physiological nasal pH. This detail affects both tolerability and absorption rate.
FAQ
What are the best peptides for brain function?
Semax, Selank, Dihexa, Cerebrolysin, and BPC-157 have the most documented human or animal evidence for cognitive or neuroprotective effects. Semax and Selank have the strongest human data among research compounds; Cerebrolysin has completed multiple human RCTs. None are FDA-approved nootropics.
Does Semax actually improve memory in humans?
Semax has completed small human trials in Russia showing BDNF upregulation and improvements in attention tasks, but most trials are small (under 60 participants) and not replicated in Western RCTs. Evidence is moderate for its BDNF mechanism, low for clinical memory improvement.
What is Dihexa and how strong is the evidence?
Dihexa is a heptapeptide derived from angiotensin IV that potently activates the HGF/Met signaling pathway, promoting dendritic growth in rodent models. All human data is currently absent; evidence is animal-only, making confidence very low for human cognitive benefit.
Is Cerebrolysin a peptide and does it work?
Cerebrolysin is a heterogeneous mixture of low-molecular-weight peptides derived from porcine brain. Multiple RCTs in stroke and Alzheimer's patients show modest improvements in cognitive scales, making it the most clinically validated option on this list, though it requires IV or IM administration.
Can BPC-157 help the brain?
BPC-157 shows neuroprotective and dopaminergic effects in rodent models, including reversal of dopamine depletion states. There are zero published human trials for neurological endpoints. Brain benefit in humans is speculative based on animal data only.
How is Selank different from Semax?
Selank is a heptapeptide analog of tuftsin with anxiolytic and mild nootropic effects, acting partly through GABAergic modulation. Semax acts primarily via BDNF and ACTH pathways. Selank is better suited to anxiety-driven cognitive impairment; Semax to attention and processing speed.
Do peptides cross the blood-brain barrier?
Most peptides are too large and too hydrophilic to cross the blood-brain barrier passively. Semax and Selank are administered intranasally specifically because the olfactory route allows partial CNS delivery bypassing the BBB. Oral peptides for brain use face near-complete proteolytic degradation in the GI tract.
What does a COA for a research peptide need to show?
A credible COA should confirm purity by HPLC (ideally above 98%), identity by mass spectrometry, and absence of endotoxins by LAL or recombinant factor C assay. Peptide sequence confirmation and water content (Karl Fischer) are bonus markers of quality.
Are nootropic peptides legal to buy?
In the United States, most peptides on this list are not FDA-approved drugs and exist in a regulatory gray area. They may be sold for research purposes but are not legal for human consumption or clinical use without a prescription or IND. Regulations differ by country.
How do peptides compare to proven nootropics like modafinil or racetams?
Modafinil has robust RCT data for wakefulness and attention in sleep-deprived individuals. Racetams have mixed evidence. Most nootropic peptides have weaker or more limited human trial data, with the exception of Cerebrolysin in specific neurological populations.
How should intranasal peptides be stored?
Lyophilized peptide powders should be stored at minus 20 degrees Celsius or colder. Once reconstituted in bacteriostatic water, most peptides degrade meaningfully within 4 to 6 weeks even when refrigerated. Repeated freeze-thaw cycles accelerate aggregation and potency loss.
Sources
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH 4-10 with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60.
- Alvarez XA, Lombardi VRM, Fernandez-Novoa L, et al. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. Journal of Neural Transmission. 2000;59:281-292.
- Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. (CASTA trial reference)
- McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics. 2013;344(1):141-154. (Dihexa/PNB-0408)
- Siebert M, Bratek M, Blaszczyk B, et al. Selank and anxiolytic activity: review of Russian clinical literature on tuftsin analogs. Available in Russian-language pharmacological literature; cited directionally.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Plosker GL, Gauthier S. Cerebrolysin: A review of its use in dementia. Drugs and Aging. 2009;26(11):893-915.
- United States Food and Drug Administration. FDA guidance on research use only products. FDA.gov.
- Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.